Studies
Hide
Study portfolio with status, priority, and links to experiments, samples, and datasets. Business and scientific purpose: this view supports faster, evidence-based drug discovery decisions across research, operations, and governance teams. Studies is connected to linked entities, metrics, and workflow actions in this workspace. Use these panels to review evidence, identify risks, and decide the next best scientific action. The view uses deterministic demo data shaped to mirror realistic drug discovery operations.
Priority Mix
| id | programId | title | lead | status | priority |
|---|---|---|---|---|---|
| ST-001 | PRG-001 | Study 1: Oncology Cohort | Dr. Alice Morgan | paused | low |
| ST-002 | PRG-007 | Study 2: Oncology Cohort | Prof. Ben Carter | planned | medium |
| ST-003 | PRG-017 | Study 3: Neurology Cohort | Daniel Osei | planned | low |
| ST-004 | PRG-003 | Study 4: Oncology Cohort | Dr. Alice Morgan | active | medium |
| ST-005 | PRG-009 | Study 5: Neurology Cohort | Prof. Ben Carter | paused | medium |
| ST-006 | PRG-017 | Study 6: Biomarker Cohort | Cara Singh | paused | low |
| ST-007 | PRG-005 | Study 7: Genomics Cohort | Cara Singh | completed | high |
| ST-008 | PRG-008 | Study 8: Biomarker Cohort | Dr. Alice Morgan | planned | low |
| ST-009 | PRG-015 | Study 9: Inflammation Cohort | Cara Singh | planned | high |
| ST-010 | PRG-019 | Study 10: Oncology Cohort | Daniel Osei | completed | low |
| ST-011 | PRG-018 | Study 11: Inflammation Cohort | Daniel Osei | completed | high |
| ST-012 | PRG-017 | Study 12: Neurology Cohort | Dr. Alice Morgan | planned | high |
| ST-013 | PRG-018 | Study 13: Genomics Cohort | Prof. Ben Carter | completed | medium |
| ST-014 | PRG-014 | Study 14: Biomarker Cohort | Cara Singh | active | low |
| ST-015 | PRG-004 | Study 15: Oncology Cohort | Cara Singh | paused | medium |
| ST-016 | PRG-017 | Study 16: Genomics Cohort | Dr. Alice Morgan | completed | low |
| ST-017 | PRG-018 | Study 17: Neurology Cohort | Daniel Osei | active | low |
| ST-018 | PRG-003 | Study 18: Inflammation Cohort | Daniel Osei | paused | medium |
| ST-019 | PRG-019 | Study 19: Oncology Cohort | Daniel Osei | completed | medium |
| ST-020 | PRG-005 | Study 20: Neurology Cohort | Dr. Alice Morgan | planned | medium |
| ST-021 | PRG-020 | Study 21: Genomics Cohort | Prof. Ben Carter | completed | low |
| ST-022 | PRG-007 | Study 22: Genomics Cohort | Dr. Alice Morgan | active | low |
| ST-023 | PRG-010 | Study 23: Oncology Cohort | Prof. Ben Carter | active | low |
| ST-024 | PRG-023 | Study 24: Inflammation Cohort | Daniel Osei | paused | high |
| ST-025 | PRG-015 | Study 25: Genomics Cohort | Dr. Alice Morgan | paused | low |
| ST-026 | PRG-009 | Study 26: Genomics Cohort | Eve Patel | planned | high |
| ST-027 | PRG-017 | Study 27: Biomarker Cohort | Prof. Ben Carter | completed | medium |
| ST-028 | PRG-016 | Study 28: Inflammation Cohort | Prof. Ben Carter | active | high |
| ST-029 | PRG-023 | Study 29: Genomics Cohort | Cara Singh | paused | low |
| ST-030 | PRG-010 | Study 30: Genomics Cohort | Prof. Ben Carter | completed | low |
| ST-031 | PRG-002 | Study 31: Oncology Cohort | Prof. Ben Carter | active | low |
| ST-032 | PRG-019 | Study 32: Biomarker Cohort | Prof. Ben Carter | active | high |
| ST-033 | PRG-005 | Study 33: Inflammation Cohort | Daniel Osei | paused | high |
| ST-034 | PRG-006 | Study 34: Genomics Cohort | Prof. Ben Carter | active | low |
| ST-035 | PRG-020 | Study 35: Oncology Cohort | Prof. Ben Carter | paused | high |
| ST-036 | PRG-015 | Study 36: Biomarker Cohort | Prof. Ben Carter | active | high |
| ST-037 | PRG-015 | Study 37: Genomics Cohort | Cara Singh | active | high |
| ST-038 | PRG-014 | Study 38: Genomics Cohort | Cara Singh | planned | low |
| ST-039 | PRG-024 | Study 39: Inflammation Cohort | Eve Patel | completed | medium |
| ST-040 | PRG-003 | Study 40: Genomics Cohort | Daniel Osei | paused | high |
| ST-041 | PRG-007 | Study 41: Oncology Cohort | Eve Patel | completed | high |
| ST-042 | PRG-016 | Study 42: Oncology Cohort | Eve Patel | planned | medium |
| ST-043 | PRG-003 | Study 43: Genomics Cohort | Daniel Osei | planned | low |
| ST-044 | PRG-016 | Study 44: Inflammation Cohort | Cara Singh | planned | low |
| ST-045 | PRG-009 | Study 45: Neurology Cohort | Eve Patel | planned | medium |
| ST-046 | PRG-014 | Study 46: Biomarker Cohort | Prof. Ben Carter | active | medium |
| ST-047 | PRG-020 | Study 47: Genomics Cohort | Prof. Ben Carter | planned | medium |
| ST-048 | PRG-001 | Study 48: Genomics Cohort | Cara Singh | completed | medium |
| ST-049 | PRG-019 | Study 49: Inflammation Cohort | Dr. Alice Morgan | active | medium |
| ST-050 | PRG-003 | Study 50: Biomarker Cohort | Cara Singh | planned | medium |
| ST-051 | PRG-001 | Study 51: Biomarker Cohort | Eve Patel | planned | low |
| ST-052 | PRG-010 | Study 52: Biomarker Cohort | Eve Patel | completed | high |
| ST-053 | PRG-002 | Study 53: Inflammation Cohort | Cara Singh | completed | low |
| ST-054 | PRG-001 | Study 54: Neurology Cohort | Prof. Ben Carter | paused | low |
| ST-055 | PRG-015 | Study 55: Biomarker Cohort | Prof. Ben Carter | active | low |
| ST-056 | PRG-018 | Study 56: Oncology Cohort | Dr. Alice Morgan | paused | low |
| ST-057 | PRG-003 | Study 57: Neurology Cohort | Prof. Ben Carter | planned | medium |
| ST-058 | PRG-016 | Study 58: Oncology Cohort | Dr. Alice Morgan | active | high |
| ST-059 | PRG-022 | Study 59: Genomics Cohort | Eve Patel | active | high |
| ST-060 | PRG-007 | Study 60: Neurology Cohort | Eve Patel | paused | low |